Author

A. Aartse

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Assay:flow cytometry· 1 Approach:genetic perturbation / CRISPR· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

K. Sliepen· 3 shared A. B. Ward· 2 shared D. Guerra· 2 shared G. Kerster· 2 shared I. Bontjer· 2 shared J. A. Burger· 2 shared J. Han· 2 shared M. Brinkkemper· 2 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

K. Sliepen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines

I. del Moral-Sanchez, E. G. Wee, Y. Xian, W.-H. Lee, J. D. Allen, A. Torrents de la Pena, R. d. P. F. Rocha, J. Ferguson, A. N. Leon, S. Koekkoek, E. E. Schermer, J. A. Burger, S. Kumar, R. Zwolsman, M. Brinkkemper, , R. W. Sanders

The paper introduces a triple tandem trimer (TTT) design for HIV-1 Env and influenza HA immunogens, showing improved trimer-specific immune responses in viral vectored vaccines.

bioRxiv · Aug 27, 2023Microbiology

A public antibody class recognizes a novel S2 epitope exposed on open conformations of SARS-CoV-2 spike

M. Claireaux, T. G. Caniels, M. de Gast, J. Han, D. Guerra, G. Kerster, B. D. van Schaik, A. Jongejan, A. I. Schriek, M. Grobben, P. J. Brouwer, K. van der Straten, Y. Aldon, J. Capella-Pujol, J. L. Snitselaar, , M. J. van Gils

The paper identifies a novel S2 epitope recognized by a public antibody class in SARS-CoV-2-reactive B cells, which becomes exposed on vaccine-optimized spike proteins.

bioRxiv · Dec 1, 2021Immunology

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

P. Brouwer, T. Caniels, K. van Straten, J. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, N. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. van Haaren, D. Guerra, J. Burger, E. Schermer, , M. van Gils

This study isolates potent neutralizing antibodies from COVID-19 patients that target multiple sites on the SARS-CoV-2 spike protein, offering insights for vaccine design and therapeutic development.

bioRxiv · May 12, 2020Microbiology